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Background: Synovial fluid (SF) is a dynamic reservoir for proteins originating from the synovial membrane,
cartilage, and plasma, and may therefore reflect the pathophysiological conditions that give rise to arthritis. Our
goal was to identify and quantify protein mediators of psoriatic arthritis (PsA) in SF.
Methods: Age and gender-matched pooled SF samples from 10 PsA and 10 controls [early osteoarthritis (OA)],
were subjected to label-free quantitative proteomics using liquid chromatography coupled to mass spectrometry
(LC-MS/MS), to identify differentially expressed proteins based on the ratios of the extracted ion current of each
protein between the two groups. Pathway analysis and public database searches were conducted to ensure these
proteins held relevance to PsA. Multiplexed selected reaction monitoring (SRM) assays were then utilized to confirm
the elevated proteins in the discovery samples and in an independent set of samples from patients with PsA and
controls.
Results: We determined that 137 proteins were differentially expressed between PsA and control SF, and 44 were
upregulated. The pathways associated with these proteins were acute-phase response signalling, granulocyte
adhesion and diapedesis, and production of nitric oxide and reactive oxygen species in macrophages. The
expression of 12 proteins was subsequently quantified using SRM assays.
Conclusions: Our in-depth proteomic analysis of the PSA SF proteome identified 12 proteins which were significantly
elevated in PsA SF compared to early OA SF. These proteins may be linked to the pathogenesis of PsA, as well serve as
putative biomarkers and/or therapeutic targets for this disease.
Keywords: Psoriatic arthritis, Early osteoarthritis, Proteomics, Mass spectrometry, Synovial fluid, Selected reaction
monitoring assays, Proteins, MediatorsBackground
Psoriatic arthritis (PsA) is an inflammatory arthritis dis-
tinguished by bone resorption and periarticular new
bone formation, and bears its name from its association
with the cutaneous disease, psoriasis [1]. PsA occurs in
up to 30% of psoriasis patients and in 85% of cases,
psoriasis precedes or occurs simultaneously with PsA
[2]. PsA has a predicted prevalence of 0.16 to 0.25% in
the general population, and is a complex, potentially dis-
abling musculoskeletal disorder often arising early in age.* Correspondence: vchandra@uhnresearch.ca
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unless otherwise stated.Patients with PsA are also associated with an increased
risk of co-morbidities, such as obesity, metabolic syn-
drome, diabetes, and cardiovascular disease [2,3]. The
etiology of psoriasis and PsA remains unclear, but studies
indicate that interaction between multiple genetic compo-
nents and environmental factors are important in the dis-
ease pathogenesis [4-6]. It is proposed that environmental
factors such as infections by streptococci [7] or articular
trauma [8], may trigger immunological alterations in gen-
etically predisposed individuals [4,9] that play important
roles in the appearance of both skin and articular dis-
ease. From the immunological point of view, changes
are observed in both innate and adaptive immunity.
Undoubtedly, the identification of key PsA mediators
will not only provide valuable information towards atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ease, but it might also uncover important PsA biomarkers
potentially useful for clinical follow-up and response to
treatment.
Mass spectrometry (MS)-based proteomic approaches
are well-suited for the discovery of protein mediators
of disease. Early studies relied on qualitative (identity-
based) analysis, and performance was depended mainly
on the sensitivity of the available MS platforms and sam-
ple processing prior to MS-analysis [10,11]. More recently,
semi-quantitative and quantitative comparisons of protein
relative abundance are the preferred methods for identify-
ing differentially expressed proteins [12]. In many cases,
chemical or metabolic labeling of samples prior to analysis
has been utilized for quantitation, but it has been associ-
ated with technical challenges [13,14]. Label-free quantifi-
cation (LFQ) methods have also been recently optimized,
in which quantification is based on the differential peak
intensity [extracted ion current (XIC)] of the peptides in
each MS scan [15,16].
LFQ quantitative proteomics presents a robust means
for obtaining proteome profiles of virtually any biological
material [15,16]. Human plasma represents a diverse
proteome and is an excellent source for protein mediators
of disease, but proteins secreted by adjacent tissues are di-
luted in blood, and are often undetectable by current MS
methods [14]. To circumvent this issue, attention has been
focused on proximal fluids, such as ascites [17], and sem-
inal fluid [18] to search for tissue-associated markers. For
instance, in the case of PsA, synovial fluid (SF) represents
an interesting source of PsA-related proteins secreted by
the synovium, ligament, meniscus, articular cartilage,
and joint capsule [19]. Moreover, it is well known, that
there is an exchange of proteins between SF and the sys-
temic circulation through the synovial lymphatics and vas-
culature [19]. In support of this, we have demonstrated
that proteins elevated in the SF of PsA patients, are like-
wise upregulated at the serum level [20]. Consequently,
we decided to focus on SF for the discovery of key PsA
mediators.
In the present study, we performed label-free MS quan-
titation of SF proteins from PsA and early osteoarthritis
(OA). Using a highly sensitive and specific MS-based ap-
proach, we confirmed the elevation of specific elevated
proteins in an independent set of samples from patients
with PsA. These observations may shed new light on the
pathogenesis of PsA, offer insights into disease progres-
sion, and might reveal potential PsA biomarkers.
Results
Delineating the PsA SF proteome
Our LC-MS/MS analysis of SF identified and quantified
443 proteins, which were present in at least two of the
three technical replicates representative of each PsA andEOA pool. Of these, 137 proteins were differentially reg-
ulated (2.0 < XIC ratio < 0.8) between the PsA and early
OA SF, as shown in Additional file 1: Table S1. A total
of 44 proteins were upregulated with a PsA/OA ratio
greater than 2, while 93 proteins were downregulated,
with a ratio less than 0.8. The IPA software was used to
identify dysregulated functional pathways associated
with both the upregulated and downregulated proteins
in the PsA SF proteome. The top five molecular and cel-
lular functions were, cell-to-cell signalling and interaction,
cell movement, antigen presentation, cell cycle, and cell
morphology, some of which have been shown to be attri-
butes of PsA [21]. The top canonical pathways associated
with these proteins were acute-phase response signalling,
granulocyte adhesion and diapedesis, and production of
nitric oxide and reactive oxygen species in macrophages
(Table 1). While some of the functions were similar, the
downregulated proteins were less associated with inflam-
matory processes (Additional file 1: Table S2). Since our
ultimate goal is to identify candidate biomarkers for PsA,
we decided to focus on proteins that were overexpressed
in PsA SF.
According to gene ontology functional annotation, the
majority of these proteins were extracellular, plasma
membrane-associated, or proteins with unknown localization
(Additional file 1: Figure S1), consistent with the fact that
SF is a proximal fluid, and most of the proteins are likely
shed or secreted by chondrocytes, synoviocytes, and in-
flammatory cells which come in direct contact with this
biological fluid [14]. Since inflammation-driven cell death
naturally occurs during PsA [22], this could lead to the re-
lease of cytosolic proteins into the SF, therefore the
cytosolic proteins we identified also hold biological
importance. We focused on proteins displaying strong ex-
pression in skin, bone, and immune regulatory cells
(Additional file 1: Table S3), but excluded immunoglobu-
lins from further analysis. This reduced our list to 20 pro-
teins, from which, high abundance serum proteins, as
identified using the Plasma Proteome Database, were ex-
cluded (SAA1, APCS, APOC1), as we assumed that these
were most likely serum contaminants from the joint aspir-
ation or arthroscopic procedure. This filtering yielded a
final set of 17 proteins (Table 2), which we deemed likely
to be associated with PsA. The validity of our discovery
approach was further enhanced by the discovery of previ-
ously investigated PsA- relevant proteins (CRP, MMP3,
S100A9) [23,24].
SRM verification of putative mediators in individual SF
samples
To verify the differences in protein expression between
PsA and early OA SF samples, as identified by LC-MS/MS,
we developed multiplexed selected reaction monitor-
ing assays. Reactions were developed for 17 peptides
Table 1 Summary of Ingenuity Pathway Analysis (IPA)-generated functional pathways and diseases associated with





Connective tissue disorders 8 ACTA1, DEFA1, IGHM, PLS2, MMP1, MMP3, MPO, S100A9 1.21E-07
Inflammatory disease 8 ACTA1, DEFA1, IGHM, PLS2, MMP1, MMP3, MPO, S100A9 1.21E-07
Skeletal and muscular disorders 8 ACTA1, DEFA1, IGHM, PLS2, MMP1, MMP3, MPO, S100A9 1.21E-07
Inflammatory response 10 CTSG, FGA, PLS2, S100A9, APCS, MPO, SAA1, DEFA1,
ORM1, MMP1
2.86E-06
Immunological disease 5 ACTA1, DEFA1, PLS2, MPO, S100A9 1.04E-04
Molecular and cellular functions
Cell-to-cell signaling and interaction 11 CTSG, FGA, PLS2, S100A9, MPO, ORM1, DEFA1, APCS,
APOC1, SAA1, MMP1
2.86E-06
Cellular movement 8 CTSG, DEFA1, SAA1, PLS2, MMP1, MMP3, S100A9, PFN1 5.69E-05
Antigen presentation 1 PLS2 2.11E-03
Cell cycle 1 PFN1 2.11E-03
Cell morphology 2 PLS2, PFN1 2.11E-03
Physiological system development and function
Hematological system development and function 10 CTSG, FGA, PLS2, S100A9, MPO, ORM1, DEFA1,
SAA1, APCS, IGHM
2.86E-06
Immune cell trafficking 10 CTSG, FGA, PLS2, S100A9, MPO, ORM1, DEFA1,
SAA1, MMP1, APCS
2.86E-06
Tissue development 8 CTSG, FGA, PLS2, S100A9, MPO, ORM1, SAA1, ACTA1 2.86E-06
Cell-mediated immune response 3 CTSG, DEFA1, PLS2 1.51E-03
Organismal survival 2 ACTB, PLS2 3.33E-03
Top canonical pathways
LXR/RXR activation 5 APOB, APOC1, FGA, ORM1, SAA1 2.70E-06
Acute phase response signaling 5 APCS, C4BP, FGA, ORM1, SAA1 1.53E-05
Clathirin-mediated endocytosis signaling 5 ACTA1, ACTB, APOB, APOC1, ORM1 2.61E-05
Granulocyte adhesion and diapedesis 4 ACTA1, ACTB, MMP1, MMP3 3.53E-04
Production of nitric oxide and
reactive oxygen species in macrophages
4 APOB, APOC1, MPO, ORM1 3.09E-04
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in the SF of PsA patients, as well as 4 peptides represent-
ing the 2 housekeeping proteins that had unchanged ex-
pression between PsA and OA SF (Table 2). Consistent
with our LC-MS/MS analysis of the pooled samples, over-
expression of 13 out of these 17 proteins was also verified
in the individual PsA SF samples (Set I), as compared
to the early OA SF (Figure 1). Each sample consisted
of two technical replicates. CRP, MMP3, and S100A9,
were amongst these 13 verified proteins. The mean fold
change of each protein and the associated P-values are
depicted in Additional file 1: Table S4.
Additionally, we also confirmed the elevation of 12 out
of the 17 proteins, in an independent set of 10 PsA, and
10 early OA SF samples (Set II). In this case, we utilized
heavy-labelled peptides in order to obtain an absolute
concentration of these peptides in SF (Figure 2). Theproteins included EPO, M2BP, DEFA1, H4, H2AFX, ORM1,
CD5L, PFN1, and C4BP, as well as our positive controls
MMP3, S100A9, and CRP. The mean fold change and
P-values corresponding to each protein from SF set II are
also depicted in Additional file 1: Table S4.
Discussion
In the present study, we performed proteomic analysis
of SF, and identified 137 proteins that were differentially
expressed between PsA and OA SF. Since one of our fu-
ture goals is to investigate these proteins as serum bio-
markers, we chose to focus only on the 44 upregulated
proteins. Moreover, these proteins were reduced to 17
promising candidates that are likely produced by the
synovial membrane, cartilage, or surrounding cells, and
are secreted into the synovial fluid compartment. The
elevation of 12 of these proteins was confirmed in an
Table 2 Fold change (FC) of seventeen elevated and








Orosomucoid 1 ORM1 2.5 WFYIASAFR
Cathepsin G CTSG 6.7 NVNPVALPR
Profilin 1 PFN1 9.0 TLVLLMGK
Histone 4 H4 8.6 VFLENVIR
Histone 2A type I A H2AFX 9.7 NDEELNK
Brain acid soluble protein 1 BASP1 7.4 ESEPQAAAEPAEAK
22 kDa interstitial collagenase MMP1 6.1 DIYSSFGFPR
Leukocyte elastase inhibitor SERPINB1 4.3 LGVQDLFNSSK
Myeloperoxidase MPO 3.9 IGLDLPALNMQR
Plastin 2 PLS2 3.9 NWMNSLGVNPR
Galectin-3-binding protein M2BP 3.8 AVDTWSWGER
C4b-binding protein C4BP 2.1 YTCLPGYVR
C-reactive protein CRP 18.7 ESDTSYVSLK
Protein S100A9 S100A9 18.9 LTWASHEK
Stromelysin 1 MMP3 10.6 VWEEVTPLTFSR
Neutrophil alpha defensin 1 DEFA1 13.1 IPACIAGER





Complement Factor I* CFI 1.0 FSVSLK
YTHLSCDK
*Denotes the housekeeping proteins, and the corresponding peptides.
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vide sensitive and specific quantification. As an internal
validation of our approach, we re-discovered a number of
proteins previously known to be involved in the context of
PsA or psoriasis progression. For example, our top 3 up-
regulated proteins (based on fold change)- S100A9 [23],
MMP3, and CRP [24]- have been extensively studied in
the context of PsA.
Psoriasis is a T-cell driven disease that causes epider-
mal hyperplasia, with an influx of autoimmune effector
cells including monocytes, neutrophils, and dendritic cells
[25]. Erythema is also an important feature of psoriasis and
is caused by increased growth and dilation of superficial
blood vessels in the skin [25]. Joint and synovial findings in
PsA are T-cell driven, as in the skin, and the prominent
hyperplasia of blood vessels in skin is echoed in the syn-
ovial membrane [26]. PsA also causes hyper proliferation
of the lining cells of the synovium, resulting in the formation
of invasive, inflammatory tissue [1,21,27]. These aspects are
reflected in the current study, through the identification of
upregulated proteins belonging to I) acute-phase response
signalling, II) granulocyte adhesion and diapedesis, III) pro-
duction of nitric oxide and reactive oxygen species inmacrophage pathways, and IV) cell-to-cell signalling and
interaction, cell movement, and antigen presentation.
One of these proteins, alpha defensin 1 (DEFA1), is
secreted by neutrophils in response to various antigens.
Elevated levels have been associated with inflammatory ac-
tivity in both rheumatoid arthritis (RA) [28] and psoriasis
[29]. Additionally, antimicrobial defense mechanisms me-
diated by DEFA1 have also been described in inflammatory
synovium [30]. Although a minor inflammatory process is
present in OA synovial tissue, PsA patients demonstrate a
more aggressive state of synovial tissue inflammation com-
pared with OA patients, therefore elevation in DEFA1 may
be a good indicator of PsA pathogenesis.
The enzyme myeloperoxidase (MPO) also seems to play
a role in the joint inflammation associated with PsA, as
we have determined that it is elevated in PsA SF. MPO is
the predominant protein present in primary granules of
circulating polymorphonuclear cells. It is a member of the
human peroxidase family, heme-containing enzymes that
play a role in host defence against infection, and is the
major enzymatic source of leukocyte-generated oxidants,
released by activated neutrophils and used as a marker of
leukocyte recruitment and function and subsequent in-
flammation [31]. Although not specifically in PsA, in the
context of arthritis, MPO has been shown to be elevated
in SF and serum derived from RA patients [31], and has
been linked to the maintenance of oxidative stress in both
psoriasis [32] and RA [33]. Since biological similarities
between PsA and RA have been previously described
in some disease processes, especially among PsA patients
with polyarticular peripheral arthritis [1,27], increased
expression of MPO may also represent an important
mediator of PsA.
Furthermore, CD5-like protein (CD5L) has been de-
scribed as an alternative ligand for CD5, a lymphoid-specific
membrane glycoprotein that is constitutively expressed in
all T cells, but expressed in highest levels in activated
T-cells [34,35]. Recently, circulating CD5 levels were
shown to be increased in RA and systemic lupus erythema-
tosus [36], and currently we have confirmed the elevation
of its ligand, CD5L, in PsA SF. Although the functional
relevance of CD5L is unknown, it may play a role in the
stimulation and regulation of the immune system [36].
Moreover, a set of recent experiments have provided evi-
dence showing that CD5 stimulation, favors Th17- over
Th1-driven polarization of naïve T-cells [37]; the functional
relevance of CD5L in this has not been investigated yet.
This is relevant since in both psoriatic skin and synovium,
while CD8+ T-lymphocytes predominate, the important
role played by the Th17 subset of CD4+ T-cells in psori-
atic disease has recently also become apparent [38,39].
Together, these findings corroborate our hypothesis, that
the proteins we have identified are relevant to PsA and
the underlying mechanisms that potentiate this disease.
Figure 1 Verification of elevated proteins in PsA synovial fluid (Set I) by selected reaction monitoring assays, normalized against
housekeeping proteins. Symbols represent SF samples from individual subjects; horizontal lines depict the mean, and vertical lines the
standard deviation. ****Indicates P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; ns: non-significant.
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be described in arthritides, which include BASP1, H2AFX,
and ORM1. Interestingly, of these, only ORM1 has been
previously associated with psoriasis, where ORM1 was
increased in the plasma of psoriatic patients [40]. The
specific function of this protein has not been determined
yet, although it is believed to be involved in aspects ofimmunosuppression [40]. We speculate that ORM1 may
have a protective role in suppressing the immune system
to decrease inflammation.
Despite these interesting findings, there are some as-
pects in the design of this study that need to be further
clarified. First, the “control” synovial fluid originated
from joints of patients with early OA, and not from
Figure 2 Verification and concentration of elevated proteins in PsA synovial fluid (Set II) by selected reaction monitoring assays,
normalized against heavy-labeled peptides. Symbols represent SF samples from individual subjects; horizontal lines depict the mean, and
vertical lines the standard deviation. ****Indicates P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; ns: non-significant.
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for two reasons. One, is that normal SF has proven diffi-
cult to obtain, and two, early OA represents an appropriate
non-inflammatory comparison, to our inflammatory
PsA SF [41].
Second, pooling of samples in the discovery phase of a
proteomic study could potentially mask meaningful dis-
crepancies among the different individual SF proteomes.
To avoid this, all pool-derived candidates were further
examined in all individual samples. While pooling of
biological replicates does not allow for statistical com-
parison, it does produce sufficient sample and increases
the likelihood of identifying proteins that are otherwise un-
detectable (low abundance) in individual samples, there-
fore allowing a more extensive proteomic coverage of the
disease’s heterogeneity. In the current study, we pooled
biological replicates and performed SCX fractionation
of each pool in triplicate. With the discovery step, we
intended to generate a comprehensive SF dataset, in order
to identify potential mediators and select SRM candidates.
We pooled our biological replicates in order to save
instrument time, but also added technical replicates to
ensure accuracy of our protein identification. Therefore,
by pooling samples as well as quantifying proteins in indi-
vidual samples as we have done, we have taken advantage
of two complementary approaches in order to obtain
more meaningful results.
Third, many groups have previously utilized albumin
depletion prior to in-gel separation [14], and subsequent
proteomic analysis, in order to simplify the SF protein
content, and reduce the dynamic range of proteins. We
chose to omit this step for the following reasons: I) albu-
min is a fundamental carrier protein, and therefore, its
depletion would result in loss of potentially important
proteins from our analysis [14], and II) including a step
of immune depletion to our analysis has the potential of
increasing the percent error and reducing the reproduci-
bility of our experiments, both of which could increase
our false discovery rate [42]. In fact, in a pilot study,
where we assessed the protein recovery following albu-
min depletion, we determined that our protein recovery
was 20-40% lower (data not shown).
As discussed previously, quantification of protein levels
has been a major challenge in proteomics [13]. We utilized
a label-free approach in order to quantify, and identify up-
regulated proteins in PsA SF. In general, the advantage of
label-free approaches over chemical labeling lies in the low
cost and the high number of samples that can be easily in-
cluded in the experiment. Potential disadvantages are
lower reproducibility, which may compromise detection
of smaller quantitative changes between samples. The
lower reproducibility mostly results from the fractionation
of peptides prior to LC-MS/MS analysis, and the subse-
quent pooling of eluted fractions, which can result inunequal/uncontrolled pooling, as was the case in the
present study. For example, based on our SCX chroma-
tographic spectra, we noticed several PsA fractions con-
tained higher protein amounts, and pooling of these
fractions could hinder the identification of low-abundance
proteins; the high-protein fractions were therefore an-
alyzed individually in the PsA group, resulting in the
higher number of SCX fractions (15, compared to 10 in
early OA,as described in the Methods section). To
ensure accuracy and reproducibility of the SCX chro-
matography, following LC-MS/MS analysis, several pep-
tides were chosen at random, and their occurrence was
monitored across fractions corresponding to the PsA
and early OA pools. Although the peptide profile was
not identical in each fraction, as several peptides in
the PsA group spanned multiple fractions, generally
the peptide having the highest abundance was found
in the same fraction when comparing early OA and PsA
groups. Additionally, the reproducibility of LFQ ex-
periments is also largely based on the timeframe of
the experiment [14]; therefore, in the present study,
we standardized the entire pipeline, from sample col-
lection and processing, to instrument setup and cali-
bration. Despite the shortcomings of the fractionation
and pooling strategy, we do verify the overexpression
of particular proteins using specific SRM assays, which
provides validity to our entire strategy.
Conclusions
Overall, this study represents the most comprehensive
proteomic analysis of PsA synovial fluid, to date. We dis-
covered and verified 12 proteins significantly elevated in
PsA SF, compared to early OA SF. Interestingly, the ma-
jority of these proteins are part of functional pathways that
are known to be dysregulated in psoriasis or PsA. These
proteins may serve as potential mediators of the patho-
genesis of PsA, and should be further investigated in func-
tional experiments. Also, a large-scale validation of these
proteins in serum is essential, in order to investigate these
proteins as putative biomarkers and/or therapeutic targets
for the detection and treatment of PsA.
Methods
SF proteomic analysis
Human subjects and clinical samples
The study received institutional review board approval
from the University Health Network, and informed con-
sent was obtained from all patients.
For the discovery phase, SF was obtained from 10 cases
with PsA (6 males, 4 females; age range 30–76 years), and
10 age- and gender-matched controls (early OA) (Set I).
PsA patients had psoriasis and satisfied the CASPAR clas-
sification criteria [43]. Inclusion criteria included symp-
tom duration ranging from 1 to 10 years (to capture both
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inflamed and accessible large joint. The inflammatory
nature of the SF, and the absence of other causes of in-
flammation, such as infection and/or crystal disease, was
confirmed by laboratory investigations.
SF from joints with early OA was obtained during a
clinically indicated arthroscopic procedure. Early OA was
defined as only a partial thickness cartilage defect in any
compartment of the knee, and further defined by a grade I
or II lesion by the Outerbridge classification [44].
For the verification (quantification) phase, an independ-
ent set of SF samples (Set II) was acquired from 10 PsA pa-
tients (7 males, 3 females; age range 21–66 years), and 10
age- and gender-matched early OA controls. Inclusion and
exclusion criteria were the same as described above.
Pre-analytical sample processing
Synovial fluid samples were stored at −80°C until use.
Samples were centrifuged upon thawing at 1800 g for
10 minutes, to remove any cell debris, and the total pro-
tein was measured in each sample using the Coomassie
(Bradford) total protein assay (Pierce Biotechnology, IL).
Equal protein amounts of each SF sample were combined,
to obtain two (1 mg total) pools (PsA vs. early OA), which
were analyzed in triplicates. Proteins in each pool were
denatured using heat (95°C for 10 minutes), reduced
with 5 mM dithiothreitol at 60°C for 45 minutes, and
alkylated with 15 mM iodoacetamide, in the dark at room
temperature for 45 minutes. Sequencing grade trypsin
(Promega, WI) was added in a 1:50 (trypsin: protein) ratio,
and allowed to digest for 18 hours at 37°C. The samples
were subsequently acidified (pH 2) using 1uL of formic
acid, to inhibit trypsin activity.
The resulting peptides were then subjected to high-
performance liquid chromatography (HPLC) using strong cat-
ion exchange (SCX) columns to reduce peptide complexity.
HPLC-SCX
Digested samples were diluted 1:2 in mobile phase A
SCX buffer (0.26 M formic acid (FA), 10% acetonitrile
(ACN); pH 2–3) and loaded directly onto a 500 μL loop
connected to a PolySULFOETHYL A column (2.1 mm×
200 mm; 5 μ; 200°A; The Nest Group Inc., MA), contain-
ing a silica-based hydrophilic, anionic polymer (poly-2-
sulfotheyl aspartamide). An Aglient 1100 HPLC (Agilent
Technologies, Germany) system was used for fraction-
ation. A 60-minute gradient was employed with a lin-
ear gradient starting at 30 minutes and consisting of
mobile phase A and mobile phase B (0.26 M FA, 10%
ACN, 1 M ammonium formate; pH-4-5) for elution of pep-
tides (flow rate 200 uL/min). The fractionation was moni-
tored at a wavelength of 280 nm, and performed in
triplicate. Fractions were collected every two minutes from
20 to 55 minutes, and those with a low peak absorbancewere pooled, resulting in a total of 10–15 fractions per sam-
ple (10 fractions for early OA replicates, and 15 fractions
for PsA replicates). This amounted to a total of 75 SCX
fractions, which were then subjected to liquid chromato-
graphic and tandem mass spectrometric analysis (LC-MS/
MS). SCX column and system performance was ensured by
running a quality control peptide mixture consisting of
1 ug/uL Alpha Bag Cell peptide, 1 ug/uL Fibrinogen frag-
ment, 5 ug/uL Human ACTH, and 5 ug/uL ACE Inhibitor
(American Protein Company, CA) after every sample.LC-MS/MS
The SCX fractions were purified through C-18 OMIX
Pipette Tips (Agilent Technologies, Germany), to remove
impurities and salts, and eluted in 5 μL of 65% MS buffer
B (90% ACN, 0.1% FA, 10% water, 0.02% Trifluoroacetc
Acid (TFA)) and 35% MS buffer A (5% ACN, 0.1% FA,
95% water, 0.02% TFA). The samples were diluted to
85 μL in MS buffer A, and injected into a nano-LC system
(Proxeon Biosystems, FL) connected online to an LTQ-
Orbitrap (Thermo Fisher Scientific, USA). A 90 minute
linear gradient reversed phase chromatography using MS
buffer A and MS buffer B, was performed at a flow rate of
400 nL/min to resolve petides on a C-18 column (75 uM ×
5 cm; Proxeon Biosystems, FL). The MS parameters were:
300 Da minimum mass, 4000 Da maximum mass, auto-
matic precursor charge selection, 10 minimum peaks per
MS/MS scan; and 1 minimum scan per group. XCalibur
software v.2.0.7 (Thermo Fisher Scientific, USA) was used
for data acquisition.Protein identification and quantification
Raw files corresponding to early OA, and PsA data sets were
uploaded into MaxQuant v. 1.2.2.2 (www.maxquant.org)
[45] and searched with Andromeda (built into MaxQuant)
[46] against the nonredundant IPI.Human v.3.71 (86, 309
sequences; released March 2010) database, which contains
both forward and reverse protein sequences. Search pa-
rameters included a fixed carbamidomethylation of cyste-
ines, and variable modifications of methionine oxidation
and N-terminal acetylation. Data was initially searched
against a “human first search” database with a parent tol-
erance of 20 ppm and a fragment tolerance of 0.5 Da in
order to calculate and adjust the correct parent tolerance
to 5 ppm for the search against the IPI.Human fasta file.
During the search, the IPI.Human fasta database was ran-
domized and false detection rate (FDR) was set to 1% at
the peptide and protein levels. Data was analyzed using
“Label-free quantification” checked, and the “Match be-
tween runs” interval was set to 2 min. Proteins were iden-
tified with a minimum of one unique peptide. “LFQ
Intensity” columns corresponding to the extracted ion
current (XIC) value of each protein in replicate early OA,
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early OA ratios (fold change; FC).
Bioinformatic analysis
To minimize false positives, we excluded from further
analysis any protein with an individual FDR > 0.05. Pro-
teins displaying an XIC value lower than 100,000 were
regarded as absent (noise). We also excluded proteins
present in only one of the three technical replicates. Av-
erages of the technical replicate XIC values were calcu-
lated for each PsA and early OA group, and ratios of
PsA/early OA were used to identify deregulated proteins.
Upregulated proteins were denoted with a PsA/early OA
ratio (FC) greater than 2, while downregulated proteins
had a PsA/early OA ratio (FC) less than 0.8. Housekeep-
ing proteins were represented with a PsA/early OA ratio
(FC) of approximately 1.0. To determine the possible ori-
gin of differentially expressed proteins at the tissue level,
and identify the most probable mediators of PsA, gene
names were checked against gene (BioGPS (http://biogps.
org/#goto=welcome) [47]), and protein (Human Protein
Atlas (http://www.proteinatlas.org/) [48]) databases, to iden-
tify proteins with strong expression in PsA-associated tissues
and cell types (skin, bone, immune cells) [49]. The Plasma
Proteome Database (http://www.plasmaproteomedatabase.
org/) [50] was employed to identify proteints present
in high-abundance in the serum, which could repre-
sent potential contaminants. Selected reaction monitoringFigure 3 Summary of the experimental design.(SRM) assays were developed for the top upregulated pro-
teins in the PsA group and housekeeping proteins, and
relative protein quantification was performed in individual
SF samples to confirm their elevation in PsA SF.
Network analysis
The list of upregulated proteins identified by LC-MS/MS
was analyzed by pathway analysis using the network-
building tool, Ingenuity Pathways Analysis (IPA; Ingenuity
Systems, www.ingenuity.com), as previously described [51].
Verification of identified proteins using SRM
SRM methods were developed for verification of protein
ratios in SF, following our in-house protocols [52].
SRM assay development
PeptideAtlas (http://www.peptideatlas.org/) was utilized to
select the most commonly observed 3–4 tryptic peptides
for the proteins of interest. Their presence was confirmed
using our LC-MS/MS identification data. The uniqueness
of peptides was verified using the Basic Local Alignment
Search Tool (BLAST; https://blast.ncbi.nlm.nih.gov/Blast.
cgi). To identify peptide fragments (transitions) to moni-
tor, in silico peptide fragmentation was performed using
Pinpoint software (Thermo Fisher Scientific, USA) and 5–6
transitions were selected for each peptide. For method
optimization, digested pooled samples of SF used in our
LC-MS/MS analysis, were loaded onto a C-18 column
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mass spectrometer (TSQ Vantage; Thermo Fisher Scientific,
USA), and approximately 350 transitions were monitored
in 6 subsequent runs. Three transitions of the most in-
tense peptides were used for subsequent quantification as-
says (Table 2).
SF sample preparation
Fifty μg of total protein of each SF sample, were dena-
tured by heat, reduced, alkylated, and trypsin-digested as
described previously. In the independent SF sample set
(Set II), heavy-labelled versions of the peptides of inter-
est (JPT Peptide Technologies, Germany) ranging from
1 to 1000 fmol/μl of sample were also added, as internal
standards. Heavy peptides had identical sequences to the
endogenous peptides, except the C-terminal lysine or ar-
ginine was labeled with 13C and 15 N. The resulting pep-
tides were purified through C-18 OMIX Pipette Tips
(Agilent Technologies, Germany), and eluted in 3 μL of
65% MS buffer B (90% ACN, 0.1% FA, 10% water, 0.02%
TFA) and 35% MS buffer A (5% ACN, 0.1% FA, 95%
water, 0.02% TFA). Samples were diluted to 40 μL of MS
buffer A, randomized, and loaded onto a C-18 column
coupled to a triple quadrupole mass spectrometer.
SRM assays
SRM assays were developed on a triple-quadrupole mass
spectrometer (TSQ Vantage; Thermo Fisher Scientific,
USA) using a nanoelectrospray ionization source (nano-
ESI, Proxeon Biosystems, FL), as previously described [52].
Briefly, a 60-minute, three-step gradient was used to
load peptides onto the column via an EASY-nLC pump
(Proxeon Biosystems, FL), and peptides were analyzed
by a multiplexed SRM method using the following param-
eters: predicted CE values, 0.002 m/z scan width, 0.01 s
scan time, 0.3 Q1, 0.7 Q3, 1.5 mTorr Q2 pressure and
tuned tube lens values. Quantification, in SF set I, was ex-
ecuted after normalization against a set of 4 peptides cor-
responding to 2 housekeeping proteins (Table 2), to offset
technical variations. Each sample was analyzed in dupli-
cate, using a 60-minute method, whereby 63 transitions
were monitored. Quantification in SF set II was executed
following normalization against the added heavy-labelled
peptides, as described earlier. Each sample was analyzed in
duplicate, using a 60-minute method, whereby 114 transi-
tions were monitored. Reproducibility of the SRM signal
was confirmed by running a quality control solution of 0.1
fmol/μL BSA, every 10 runs.
SRM protein quantification
Raw files recorded for each sample were analyzed using
Pinpoint software (Thermo Fisher Scientific, USA) [53],
and peptide XICs were extracted. Pinpoint was used for
identification and visualization of transitions, as well asmanual verification of co-elution of heavy and endogen-
ous peptides. In the first SF set, in order to control for
technical variation between the samples, XIC correspond-
ing to each endogenous peptide replicate were divided by
the XIC corresponding to the average of the two house-
keeping proteins. This value was then averaged amongst
the two replicate runs, to obtain “XIC Average normalized
to housekeeping proteins”. In SF set II, in order to control
for technical variation between the samples and obtain a
more robust quantitative value for our proteins of interest,
the XIC value corresponding to each endogenous peptide,
was divided by the XIC value corresponding to each
spiked-in heavy peptide, in order to obtain a L:H (light:
heavy) ratio. Since we added a known amount of each
heavy peptide to our samples prior to analysis, we used
the L:H ratio to calculate the relative concentration of
each endogenous peptide corresponding to our proteins
of interest.
Statistical analysis
Results were analyzed using nonparametric statistics with
the Mann–Whitney U test. P-values (P) less than 0.05 were
considered statistically significant.
The overall experimental design is provided in Figure 3.
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Additional file 1: Table S1. Differentially expressed proteins between
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mediators in Set I and II*. Figure S1. Cellular localization of the 44
upregulated proteins based on GO annotation. The numbers depicted
in the chart represent the number of proteins with the specified
cellular localization.
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